Immuno-Oncology

OncLive interviewed Jason J. Luke, MD, who discussed the clinical implications of immunotherapies in melanoma, with optimal sequencing and combinations emerging as the most pressing questions that researchers are seeking to answer in ongoing clinical trials.

Elizabeth A. Mittendorf, MD, PhD, differentiates the main types of immunotherapy, highlights some of the most interesting results in breast cancer trials, and discusses why different types of immunotherapy might be appropriate for different types of breast tumors at various stages of development.

In an interview with OncLive, Ahmad A. Tarhini, MD, PhD, discussed the benefits and challenges of ipilimumab and other immunotherapies and how they could change the adjuvant treatment paradigm for melanoma.

With no major advances in survival in bladder cancer in more than 30 years, interest is high in the potential to deploy immunotherapeutic approaches in this setting.

In an interview with OncLive, Leonard G. Gomella discusses the benefits, limitations, and considerations of sipuleucel-T for patients with prostate cancer.

Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center discusses the potential for immunotherapy for the treatment of bladder cancer.

Jason J. Luke, MD, FACP, assistant professor of medicine, Melanoma and Developmental Therapeutics Clinic, University of Chicago Medicine, discusses PD-1 inhibitors nivolumab and pembrolizumab as frontline immunotherapy choices for patients with melanoma.

Sundar Jagannath, MD, director of the multiple myeloma program, professor of medicine (hematology and medical oncology), Tisch Cancer Institute at Mount Sinai School of Medicine, discusses immunotherapy in multiple myeloma and how it fits into the future treatment paradigm.

Kevin B. Kim, MD, medical oncology, California Pacific Medical Center, discusses how treatment outcomes in melanoma have evolved over the last few years.

A nearly $1 billion windfall licensing agreement involving the immunotherapy PROSTVAC has the company Bavarian Nordic looking toward a long-term manufacturing and distribution arrangement with Bristol-Myers Squibb.

Acting 3 months ahead of schedule, the FDA approved nivolumab (Odivo) for patients with squamous non-small cell lung cancer.

The FDA has accepted a supplemental Biologics License Application for ipilimumab for the adjuvant treatment of patients with stage III melanoma at high risk of recurrence following complete resection.

An investigational antibody that targets programmed death-ligand 1 (PD-L1) in combination with bevacizumab had strong antitumor activity and induced responses in 4 of 10 patients with metastatic renal cell carcinoma (mRCC) in an open-label phase Ib study.

The FDA has granted a priority review to nivolumab for use in patients with previously treated, advanced, squamous non–small cell lung cancer.